Human Pluripotent Stem Cell-Derived Islet Organoid for Diabetes Treatment

Nordia Biotech & Pharmaceuticals is a spin-off company from LKS Faculty of Medicine, HKU. It was founded on 2023.12, by Prof. ZHOU Zhongjun, the Chui Fook-Chuen Endowed Professor from HKUMed with over 30 years of experiences in development, aging and age-associated diseases, together with his former PhD student, HE Yi who developed the core technology. Our team members are very experienced in investment, financing, transformation and operation.

Nordia Biotech targets on the unmet medical needs, specifically the diabetes mellitus, with functional islet organoids generated from stem cells through a self-developed unique patented method enabling spontaneous formation of 3D structure of islets. The islet organoids will be transplanted into the anterior sheath of the rectus abdominis muscle of patients, for long-term control of blood glucose levels by steady insulin secretion. Other products includes biomaterial scaffolds to encapsulate islets organoids to increase the transplantation efficiency. The company offers islet-based contract research services, islet products as well.

Nordia Biotech finished its 5M+ USD equity investment, and received the non-equity support from ITC of HK including TSSSU+, IncuBio and RAISe+ Schemes.